Published in Nat Rev Gastroenterol Hepatol on February 01, 2010
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest (2011) 1.47
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. Am J Gastroenterol (2016) 0.90
Mucosal healing and deep remission: what does it mean? World J Gastroenterol (2013) 0.87
Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol (2011) 0.86
Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Dig Dis Sci (2015) 0.84
Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease. Dig Dis Sci (2015) 0.83
The PIRO (predisposition, insult, response, organ dysfunction) model: toward a staging system for acute illness. Virulence (2013) 0.83
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Oral Manifestations of Crohn's Disease: A Case Report and Review of the Literature. Case Rep Dent (2015) 0.80
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol (2014) 0.80
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther (2016) 0.79
Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. J Biol Chem (2014) 0.79
Biologics in paediatric Crohn's disease. Gastroenterol Res Pract (2011) 0.78
Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J (2014) 0.75
Clinical and genetic factors predicting response to therapy in patients with Crohn's disease. United European Gastroenterol J (2014) 0.75
Disseminated Tuberculosis in a Patient Taking Anti-TNF Therapy for Crohn's Disease. ACG Case Rep J (2015) 0.75
How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes. Dig Dis Sci (2014) 0.75
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum (2005) 8.47
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Inflammatory bowel disease: cause and immunobiology. Lancet (2007) 6.07
Predictability of the postoperative course of Crohn's disease. Gastroenterology (1990) 5.30
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (2009) 5.03
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology (2007) 4.83
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 4.08
Predictors of Crohn's disease. Gastroenterology (2006) 3.96
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology (2000) 3.84
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut (1988) 2.51
Clinical features and natural history of Crohn's disease. Gastroenterology (1979) 2.43
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25
Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol (1995) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol (2006) 2.03
A controlled double blind study of azathioprine in the management of Crohn's disease. Gut (1995) 2.00
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res (2009) 1.82
Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology (1990) 1.79
Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology (1993) 1.74
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut (2007) 1.64
Early versus late surgery for ileo-caecal Crohn's disease. Aliment Pharmacol Ther (2007) 1.60
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol (2003) 1.55
Predictors of severe Crohn's disease. Scand J Gastroenterol (2008) 1.47
Intensive intravenous treatment of ulcerative colitis. Gastroenterology (1985) 1.43
Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg (2005) 1.33
Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther (2006) 1.32
The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology (2002) 1.20
Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol (2009) 1.19
Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut (2007) 1.18
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17
Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol (1996) 1.12
Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol (2006) 1.12
Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther (2004) 1.09
Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am (2009) 1.02
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis (1999) 0.96
Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol (1998) 0.88
Pouchitis. World J Gastroenterol (2007) 0.87
The European consensus on ulcerative colitis: new horizons? Gut (2008) 0.83
Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut (2007) 0.82
Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis. Dis Colon Rectum (2004) 0.78